February 15, 2022

Re: Renewal of July 19, 2021 Return to Work Agreement

Gentlemen:

This letter is to memorialize the parties’ agreement regarding the renewal of the Return to Work Agreement dated July 19, 2021, which was extended to February 13, 2022. The parties have agreed to renew the Return to Work Agreement effective February 14, 2022 and through April 30, 2022, with the following modifications:
1. **Definition of “Fully Vaccinated”**

Modify the definition of “fully vaccinated” in Item 2.b.i. of Parts I and II to provide as follows:

a. Effective March 15, 2022 for individuals employed in the United States, and April 1, 2022 for individuals who are employed outside the U.S., only individuals who are “up to date” on their vaccines, as that term is defined by the CDC, shall be considered “fully vaccinated” under the Return to Work Agreement. (For clarity, an individual who has received a primary series of vaccine as outlined by the CDC need not receive a booster dose until eligible in order to be “up to date.”)

b. Individuals who have received a Novavax or AstraZeneca vaccine shall be considered “fully vaccinated” for all purposes under the Return to Work Agreement as long as the individual has received at least three vaccine doses, which may be any combination of a vaccine approved or authorized for emergency use by the U.S. FDA, Novavax, or AstraZeneca.

2. **Masks**

When masks are required, individuals shall wear a KN95, KF94, N95 mask, or when there is a fit issue, a well-fitting surgical mask, and such masks shall be provided by the Employer.

3. **Temporary COVID-19 Sick Leave**

All employees shall have a total of ten (10) days of temporary COVID-19 paid sick leave per Producer, which may be used during the period beginning on February 14, 2022 and ending on September 30, 2022, and which may cover one or more Eligible COVID-19 Events.

4. **Antigen Tests**

The following antigen tests are mutually agreed upon by the parties and may only be used when antigen tests are expressly authorized by the Agreement:

a. BD Veritor system (Becton Dickinson)
b. BinaxNow (Abbot Diagnostics)
c. CareStart (Access Bio)
d. Celltrion Diatrust Ag Home Test
e. CLINITEST Rapid COVID-19 Antigen (Seimens)
f. Flowflex (ACON Laboratories, Inc)
Renewal of July 19, 2021 Return
to Work Agreement
February 15, 2022
Page 3

g. GenBody COVID-19 Ag Rapid Antigen Test
h. Indicaid (PHASE Scientific International)
i. InteliSwab (OraSure Technologies, Inc)
j. LumiraDx (LumiraDx)
k. QuickVue (Quidel)
l. SCoV-2 Ag Detect (InBios)
m. SDBiosensor
n. Sienna Clarity (Salofa Oy)
o. Sofia (Quidel Corp)

The Unions also agree to review additional tests in Canada to add to the list of approved antigen tests.

Sincerely,

Carol A. Lombardini
CAL;vwI

ACCEPTED AND AGREED:

By: ____________________________
    Duncan Crabtree-Ireland
    on behalf of SAG-AFTRA

ACCEPTED AND AGREED:

By: ____________________________
    Steve Dayan
    on behalf of the Basic Crafts Unions
    and Teamsters Local #399 Location
    Managers and Casting Directors

ACCEPTED AND AGREED:

By: ____________________________
    Russell Hollander
    on behalf of the DGA

ACCEPTED AND AGREED:

By: ____________________________
    Matthew D. Loeb
    on behalf of the IATSE

ACCEPTED AND AGREED:

By: ____________________________
    Thomas J. O’Donnell
    on behalf of Teamsters Local #817
    and Casting Directors